Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management
JN Brudno, JN Kochenderfer - Blood reviews, 2019 - Elsevier
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA:
tisagenlecleucel for pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-
cell lymphoma subtypes (DLBCL), and axicabtagene ciloleucel for DLBCL. CAR T-cell
therapies are being developed for multiple myeloma, and clear evidence of clinical activity
has been generated. A barrier to widespread use of CAR T-cell therapy is toxicity, primarily …
malignancies. Two CAR T-cell products are now approved for clinical use by the US FDA:
tisagenlecleucel for pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-
cell lymphoma subtypes (DLBCL), and axicabtagene ciloleucel for DLBCL. CAR T-cell
therapies are being developed for multiple myeloma, and clear evidence of clinical activity
has been generated. A barrier to widespread use of CAR T-cell therapy is toxicity, primarily …